Taken together, our study indicates that BCAR3 is a novel antagonist of TGFβ proinvasive functions in breast cancer cells, and loss of BCAR3 function correlates with poor outcomes in breast cancer patients. The gene discussed is TGFB1; the disease is breast carcinoma.